Provided by Tiger Trade Technology Pte. Ltd.

ADC Therapeutics SA

1.73
+0.14008.81%
Post-market: 1.730.00000.00%19:37 EDT
Volume:3.14M
Turnover:5.40M
Market Cap:219.79M
PE:-2.38
High:1.83
Open:1.58
Low:1.56
Close:1.59
52wk High:4.98
52wk Low:0.7796
Shares:127.04M
Float Shares:88.56M
Volume Ratio:1.34
T/O Rate:3.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7271
EPS(LYR):-1.1224
ROE:-705.53%
ROA:-19.57%
PB:-0.96
PE(LYR):-1.54

Loading ...

ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says

MT Newswires Live
·
Yesterday

ADC Therapeutics Shares Rise After Financial Restructuring Extends Cash Runway

MT Newswires Live
·
Yesterday

ADC Therapeutics announces comprehensive strategic financial restructuring

TIPRANKS
·
Oct 08

ADC Therapeutics Restructures Balance Sheet with $86.6 Million PIPE Financing

Reuters
·
Oct 08

ADC Therapeutics - Sells 12.9 Mln Shares at $1.42 and 48.1 Mln Pre-Funded Warrants at $1.32

THOMSON REUTERS
·
Oct 08

ADC Therapeutics - Expects Q3 Net Product Revenues from Zynlonta Sales of $21 Mln

THOMSON REUTERS
·
Oct 08

ADC Therapeutics - Refinanced Senior Secured Loan, Principal Reduced to $50 Mln, Bullet Payment August 2029

THOMSON REUTERS
·
Oct 08

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

THOMSON REUTERS
·
Oct 08

ADC Therapeutics - Pipe Gross Proceeds Expected to be $86.60 Mln Before Fees

THOMSON REUTERS
·
Oct 08

ADC Therapeutics - Amended Healthcare Royalty Agreement Removing Change-of-Control Payment

THOMSON REUTERS
·
Oct 08

These Beaten-Down Stocks Could Bounce Back in January, if History is Any Guide

Dow Jones
·
Sep 22

ADC Therapeutics Highlights Zynlonta Growth Opportunity in Corporate Presentation

Reuters
·
Sep 10

ADC Therapeutics CEO Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 03

ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says

MT Newswires Live
·
Aug 14

UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101

Reuters
·
Aug 14

ADC Therapeutics SA Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

ADC Therapeutics Sa - Q2 Net Product Revenue of $18.6 Million, Net Loss $0.11 Per Share

THOMSON REUTERS
·
Aug 13

ADC Therapeutics Posts Corporate Presentation Highlighting Zynlonta Growth Opportunity in B-Cell Lymphomas

Reuters
·
Aug 13

ADC Therapeutics Q2 Income from Operations USD -25.414 Million Vs. IBES Estimate USD -24.4 Million

Reuters
·
Aug 13

ADC Therapeutics Q2 FY26 Net Loss Narrows 70.75% to $16.6 Million; Revenue Rises 2.99% to $19.25 Million

Reuters
·
Aug 13